COVID-19: Thromboserisiko und Antikoagulationsmanagement

Bereits früh im Verlauf der COVID-19-Pandemie wurde eine Häufung von Thromboembolien bei schwer an COVID-19 erkrankten Patienten beobachtet. In frühen Berichten über Patienten aus Wuhan und aus New York wurde ein Zusammenhang zwischen erhöhten D-Dimeren und der Wahrscheinlichkeit, an der Erkrankung zu versterben, beobachtet.

Schlüsselwörter

COVID-19 - Thromboembolieprophylaxe - Antikoagulation - Lungenembolie

• Literatur

• 1 Iba T, Levy JH, Levi M. et al. Coagulopathy of Coronavirus Disease 2019. Crit Care Med 2020; 48: 1358-1364
• 2 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-1062
• 3 Cummings MJ, Baldwin MR, Abrams D. et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020; 395: 1763-1770
• 4 Ackermann M, Verleden SE, Kuehnel M. et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med 2020; 383: 120-128
• 5 Pons S, Fodil S, Azoulay E. et al. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care 2020; 24: 353
• 6 Varga Z, Flammer AJ, Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417-1418
• 7 Jimenez D, Garcia-Sanchez A, Rali P. et al. Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. Chest 2021; 159: 1182-1196
• 8 Wichmann D, Sperhake JP, Lutgehetmann M. et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med 2020; 173: 268-277
• 9 Bemtgen X, Zotzmann V, Benk C. et al. Thrombotic circuit complications during venovenous extracorporeal membrane oxygenation in COVID-19. J Thromb Thrombolysis 2021; 51: 301-307
• 10 Doyle AJ, Hunt BJ, Sanderson B. et al. A Comparison of Thrombosis and Hemorrhage Rates in Patients With Severe Respiratory Failure Due to Coronavirus Disease 2019 and Influenza Requiring Extracorporeal Membrane Oxygenation. Crit Care Med 2021; 49: e663-e672
• 11 Seeliger B, Doebler M, Hofmaenner DA. et al. Intracranial Hemorrhages on Extracorporeal Membrane Oxygenation: Differences Between COVID-19 and Other Viral Acute Respiratory Distress Syndrome. Crit Care Med 2022; 50: e526-e538
• 12 Poissy J, Goutay J, Caplan M. et al. Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence. Circulation 2020; 142: 184-186
• 13 Lopes RD, de Barros ESPGM, Furtado RHM. et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 2021; 397: 2253-2263
• 14 ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators. et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med 2021; 385: 790-802
• 15 Nopp S, Moik F, Jilma B. et al. Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Res Pract Thromb Haemost 2020; 4: 1178-1191
• 16 Bilaloglu S, Aphinyanaphongs Y, Jones S. et al. Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. JAMA 2020; 324: 799-801
• 17 Vincent JL, Levi M, Hunt BJ. Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia. Lancet Respir Med 2022; 10: 214-220
• 18 Perico L, Benigni A, Casiraghi F. et al. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol 2021; 17: 46-64
• 19 Bonaventura A, Vecchié A, Dagna L. et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol 2021; 21: 319-329
• 20 Wagner DD, Heger LA. Thromboinflammation: From Atherosclerosis to COVID-19. Arterioscler Thromb Vasc Biol 2022; 42: 1103-1112
• 21 Osuchowski MF, Winkler MS, Skirecki T. et al. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med 2021; 9: 622-642
• 22 Remmelink M, De Mendonca R, D’Haene N. et al. Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients. Crit Care 2020; 24: 495
• 23 Del Valle DM, Kim-Schulze S, Huang HH. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 2020; 26: 1636-1643
• 24 Ward SE, Fogarty H, Karampini E. et al. ADAMTS13 regulation of VWF multimer distribution in severe COVID-19. J Thromb Haemost 2021; 19: 1914-1921
• 25 Zuo Y, Warnock M, Harbaugh A. et al. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci Rep 2021; 11: 1580
• 26 Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med 2020; 383: 2451-2460
• 27 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506
• 28 Vincent JL. COVID-19: it’s all about sepsis. Future Microbiol 2021; 16: 131-133
• 29 Gurbel PA, Tantry US, Storey RF. International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests. J Thromb Thrombolysis 2021; 52: 992-998
• 30 Barrett TJ, Lee AH, Xia Y. et al. Platelet and Vascular Biomarkers Associate With Thrombosis and Death in Coronavirus Disease. Circ Res 2020; 127: 945-947
• 31 Leentjens J, van Haaps TF, Wessels PF. et al. COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year. Lancet Haematol 2021; 8: e524-e533
• 32 Konstantinides SV, Meyer G, Becattini C. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41: 543-603
• 33 Connors JM, Brooks MM, Sciurba FC. et al. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. JAMA 2021; 326: 1703-1712
• 34 Ananworanich J, Mogg R, Dunne MW. et al. Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19. Clin Infect Dis 2022; 75: e473-e481
• 35 Spyropoulos AC, Goldin M, Giannis D. et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med 2021; 181: 1612-1620
• 36 Sholzberg M, Tang GH, Rahhal H. et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ 2021; 375: n2400
• 37 Kluge S, Janssens U, Welte T. et al. S3-Leitlinie – Empfehlungen zur stationären Therapie von Patienten mit COVID-19 (12.09.2022). AWMF-Register-Nr. 113/001. Accessed November 21, 2022 at: https://register.awmf.org/assets/guidelines/113-001LGl_S3_Empfehlungen-zur-stationaeren-Therapie-von-Patienten-mit-COVID-19_2022-09_1.pdf
• 38 REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators. et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med 2021; 385: 777-789
• 39 Sadeghipour P, Talasaz AH. INSPIRATION Investigators. et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA 2021; 325: 1620-1630
• 40 Perepu US, Chambers I, Wahab A. et al. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial. J Thromb Haemost 2021; 19: 2225-2234
• 41 Ramacciotti E, Barile Agati L, Calderaro D. et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet 2022; 399: 50-59